Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Bausch + Lomb Corporation stock (Bausch + Lomb Corporation)

Learn how to buy Bausch + Lomb Corporation stock in 5 easy steps.

Bausch + Lomb Corporation, an eye health company responsible for producing popular contact lens brands like Biotrue and Soflens, has gone public with an IPO. Shares were priced at $18, below the expected range. and rose slightly to around $19 in their first morning of trading on May 6.

Our top picks for where to buy Bausch + Lomb Corporation stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Bausch + Lomb Corporation stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BLCO. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Bausch + Lomb Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
OPTO
Not rated yet
OPTO
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
★★★★★
Stocks, ETFs, Cryptocurrency
$0
$0
4.5%
N/A
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Bausch + Lomb Corporation stock price (NYSE: BLCO)

Use our graph to track the performance of BLCO stocks over time.

Bausch + Lomb Corporation shares at a glance

Information last updated 2022-05-24.
Latest market close$15.84
52-week range$15.90 - $20.20
50-day moving average $17.27
200-day moving average $17.27
Wall St. target price$35.00
PE ratio 33.82
Dividend yield $0 (0%)
Earnings per share (TTM) $0.50

Is it a good time to buy Bausch + Lomb Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bausch + Lomb Corporation price performance over time

Historical closes compared with the close of $15.84 from 2024-07-15

1 week (2024-07-10) 2.39%
1 month (2024-06-17) 6.02%
3 months (2024-04-17) 10.69%
6 months (2024-01-17) 7.54%
1 year (2023-07-17) -23.26%
2 years (2022-07-15) 1.60%
3 years (2021-07-13) N/A
5 years (2019-07-13) N/A

Is Bausch + Lomb Corporation stock undervalued or overvalued?

Valuing Bausch + Lomb Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bausch + Lomb Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bausch + Lomb Corporation's P/E ratio

Bausch + Lomb Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Bausch + Lomb Corporation shares trade at around 34x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Bausch + Lomb Corporation's P/E ratio is best considered in relation to those of others within the medical instruments & supplies industry or those of similar companies.

Bausch + Lomb Corporation's EBITDA

Bausch + Lomb Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $720 million.

The EBITDA is a measure of a Bausch + Lomb Corporation's overall financial performance and is widely used to measure a its profitability.

To put Bausch + Lomb Corporation's EBITDA into context you can compare it against that of similar companies.

Bausch + Lomb Corporation financials

Revenue TTM $3.8 billion
Operating margin TTM 8.38%
Gross profit TTM $2.3 billion
Return on assets TTM 0%
Return on equity TTM 2.16%
Profit margin 4.64%
Book value $20.40
Market Capitalization $5.9 billion

TTM: trailing 12 months

Bausch + Lomb Corporation share dividends

We're not expecting Bausch + Lomb Corporation to pay a dividend over the next 12 months.

You may also wish to consider:

Bausch + Lomb Corporation overview

Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada. .

Frequently asked questions

null
What percentage of Bausch + Lomb Corporation is owned by insiders?
Currently 0.256% of Bausch + Lomb Corporation shares are held by insiders.
How many people work for Bausch + Lomb Corporation?
Latest data suggests 19,600 work at Bausch + Lomb Corporation.
When does the fiscal year end for Bausch + Lomb Corporation?
Bausch + Lomb Corporation's fiscal year ends in December.
Where is Bausch + Lomb Corporation based?
Bausch + Lomb Corporation's address is: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site